SCHEMBL264360

SCHEMBL264360

COC(C)(c1ccc2cc(C(=O)NCc3ccnc4ccccc34)ccc2c1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.48
MAPT P10636 1/20 0.44
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 2/20 0.43
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
MMP2 P08253 1/20 0.41
MMP13 P45452 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
HPGDS O60760 1/20 0.41
EPHX2 P34913 2/20 0.40
EGLN1 Q9GZT9 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
RAF1 P04049 1/20 0.40
LCK P06239 1/20 0.40
RET P07949 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL269559 0.86 SMN1; SMN2 (0.49) SMN1; SMN2MAPTKDM4EMEN1ALDH1A1
SCHEMBL4787180 0.86 FLT1 (0.48) SMN1; SMN2MAPTKDM4EALDH1A1ADORA2A
SCHEMBL263858 0.79 SMN1; SMN2 (0.43) SMN1; SMN2MAPTKDM4EALDH1A1ADORA2A
SCHEMBL263929 0.74 SMN1; SMN2 (0.45) SMN1; SMN2MAPTKDM4EMEN1ALDH1A1
SCHEMBL264854 0.73 MMP2 (0.47) SMN1; SMN2MAPTKDM4EMEN1ALDH1A1
SCHEMBL14147908 0.73 SCN9A (0.52) MEN1KMT2AADORA2AADORA1KDR
SCHEMBL263436 0.73 MEN1 (0.47) MEN1ALDH1A1KMT2AADORA2AADORA1
Hydrochloric Acid SCHEMBL264982 0.72 MEN1 (0.47) MEN1ALDH1A1KMT2AADORA2AADORA1
SCHEMBL263146 0.71 PTPN11 (0.54) KDM4EALDH1A1LMNAHTTLCK
SCHEMBL264812 0.70 TRPV1 (0.39) SMN1; SMN2MAPTALDH1A1KMT2ATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US claimed
EP-2044018-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS Pfizer Japan, Inc. (JP) 2009-04-08 EP claimed
WO-2008007211-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2008-01-17 WO claimed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
WO-2008007211-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS OPRL1, CNR1, TRPV1 SMN1; SMN2 1166/4885MAPT 4405/4885KDM4E 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.